Research programme: casein kinase inhibitors - Pfizer
Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Pfizer
- Class Pyrazoles; Pyrimidines
- Mechanism of Action Casein kinase 1 epsilon inhibitors; Casein kinase Idelta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Psychiatric disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA
- 04 Nov 2017 No recent reports of development identified for research development in Psychiatric-disorders in USA
- 01 Sep 2011 Early research is ongoing in USA